Kura Oncology (NASDAQ:KURA) Trading 5.5% Higher - Should You Buy?

Shares of Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) rose 5.5% during trading on Monday . The company traded as high as $6.19 and last traded at $6.23. Approximately 79,864 shares were traded during trading, a decline of 95% from the average daily volume of 1,515,990 shares. The stock had previously closed at $5.90.

Wall Street Analyst Weigh In

KURA has been the topic of a number of research reports. StockNews.com upgraded Kura Oncology from a "hold" rating to a "buy" rating in a report on Friday, April 4th. HC Wainwright restated a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a report on Thursday, February 27th. UBS Group decreased their price target on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Scotiabank lowered their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Kura Oncology has an average rating of "Moderate Buy" and a consensus target price of $25.50.

Kura Oncology Stock Performance

The company has a market capitalization of $519.40 million, a PE ratio of -2.72 and a beta of 0.83. The stock's 50-day simple moving average is $6.88 and its 200 day simple moving average is $9.99. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analysts' expectations of $57.96 million. As a group, research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Activity at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the firm's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company's stock, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock valued at $92,307 over the last ninety days. Insiders own 6.40% of the company's stock.

Institutional Trading of Kura Oncology

A number of institutional investors have recently modified their holdings of KURA. Virtus ETF Advisers LLC lifted its stake in shares of Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after purchasing an additional 3,061 shares during the period. Pallas Capital Advisors LLC purchased a new stake in shares of Kura Oncology during the first quarter worth about $66,000. Flower City Capital acquired a new position in Kura Oncology in the 1st quarter valued at $79,000. Harbor Advisors LLC acquired a new position in Kura Oncology in the fourth quarter valued at $87,000. Finally, E Fund Management Co. Ltd. purchased a new position in shares of Kura Oncology during the 4th quarter worth about $90,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.